Malignant Perivascular Epithelioid Cell Tumor

• CLINICAL_TRIALS trial_result · 2022-11-28
  Clinical Trial Update: A Study of Safety and Efficacy of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumor (PEComa) [Phase 1, Phase 2]

  Clinical trial update for sirolimus (albumin-bound) in advanced malignant PEComa across Phase 1 and Phase 2.

• FDA approval · 2021-11-22
  FDA Approved: FYARRO — Original Application (Aadi Bioscience, Inc.)

  FDA approved FYARRO (sirolimus) from Aadi Bioscience in an original application for the treatment of adult patients with malignant perivascu…

• CLINICAL_TRIALS withdrawal · 2013-08-02
  Clinical Trial Update: A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa [Phase 2]

  The Phase II trial of BEZ235 (dactolisib) as monotherapy for malignant perivascular epithelioid cell tumor has been withdrawn.